Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    5-HT1B/1D- and 5-HT1A antagonists: central 5-HT release and turnover (2005)

    Art
    Poster
    Autoren
    Rex, A.
    Platz, E.
    Voigt, J. P.
    Wicke, K.
    Fink, H.
    Kongress
    8th World Congress of Biological Psychiatry
    Wien/Österreich, 28.06. – 03.07.2005
    Quelle
    The world journal of biological psychiatry; Vol. 6(Suppl 1) — S. 334
    ISSN: 1814-1412
    Sprache
    Englisch
    Kontakt
    Institut für Pharmakologie und Toxikologie

    Koserstr. 20
    14195 Berlin
    +49 30 838 53221
    pharmakologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    5-HT1B/1D- and 5-HT1A antagonists: central 5-HT release and turnover

    Objectives: Serotonin 5-HT1A and 5-HT1B/1D receptors control serotonin (5-HT) release in the CNS. They are targets for the pharmacological treatment of psychiatric disorders.
    Methods: We investigated effects of the 5-HT1B/1D antagonist GR127935 (10 µM perfused into the frontal cortex), the 5-HT1A antagonist WAY100635 (1 mg/kg i.p.) and a combination of both on cortical 5-HT release in guinea pigs using in vivo microdialysis in comparison to reference drugs as the 5-HT releaser d-fenfluramine and the 5-HT1A agonist 8-OH-DPAT. The tissue content of 5-HT and 5-HT turnover (5-HIAA/5-HT ratio) was also determined in brain regions ex vivo.
    Results: Microdialysis: As references, the 5-HT releasing agent d-fenfluramine and the 5-HT1A agonist 8-OH-DPAT increased and decreased cortical 5-HT release, respectively.
    Systemic administration of WAY100635, perfusion with GR127935 in the frontal cortex or the combination of both treatments had no significant effect on extracellular 5-HT.
    5-HT content and 5-HT turnover: 5-HT and 5-HT turnover were determined in a sample containing i) the median and dorsal raphe nuclei, ii) the frontal cortex or iii) the ventral hippocampus. Compared to controls WAY100635, GR127935 and the combination thereof, decreased cortical 5-HT (-30%), and increased 5-HT turnover in the cortex (270%) as well as in the raphe nuclei (180%). WAY100635 decreased hippocampal 5-HT (-40%), while both drugs and their combination increased hippocampal 5-HT turnover (200%) compared to controls. Combined treatment had no superior or additive effects.
    Conclusions: The region-specific decrease in 5-HT and the concomitant increase in local 5-HT turnover suggest that both 5-HT1 antagonists have subtle effects on 5-HT function.